(Phleum pratense)<\/em>-Pr\u00e4parates. Allergo Journal 23[6], 75. 2014.
\nRef Type: Abstract<\/p>\n(17) \u00a0 Rudert M, Hansen S, H\u00e4fner D, L\u00fcbcke P, Narkus A. Responderanalyse der Intrakutantest (ICT) – Reaktivit\u00e4t in einer Dosisfindungsstudie mit einem hochdosierten, hypoallergenen Wiesenlieschgras- (Phleum pratense) Pr\u00e4parat. Allergo Journal 23[6], 74-75. 2014.
\nRef Type: Abstract<\/p>\n
(18) \u00a0 Teichmann P, Homolla V, Goedicke V, Karjalainen M, Narkus A, H\u00e4fner D. Vertr\u00e4glichkeit einer verk\u00fcrzten Aufdosierung mit einem hochdosierten, hypoallergenen Gr\u00e4serpollenpr\u00e4parat. Allergo Journal 23[6], 73. 2014.
\nRef Type: Abstract<\/p>\n
(19) \u00a0 Haefner D, Meyer H, Weber B, Kettner J, Narkus A. Immunogenic activity of pollen allergoids. Allergy 68[S97], 471. 2013.
\nRef Type: Abstract<\/p>\n
(20) \u00a0 Haefner D, Meyer H, Weber B, Kettner J, Narkus A. Effects of treatment with sublingual and subcutaneous grass pollen specific immunotherapy preparations on IgG4 antibody level. Allergy 68[S97], 550. 2013.
\nRef Type: Abstract<\/p>\n
(21) \u00a0 Haefner D, Tribanek M, Kettner J, Narkus A. Effects of subcutaneous specific immunotherapy with recombinant hypoallergenic Bet v 1 folding variant (rBet v 1-FV) on asthma symptoms. Allergy 68[S97], 475-476. 2013.
\nRef Type: Abstract<\/p>\n
(22) \u00a0 Homolla V, H\u00e4fner D, Tribanek M, Kettner J, Narkus A. Wirksamkeit der subkutanen spezifischen Immuntherapie (SCIT) mit einer hypoallergenen rekombinanten Bet v 1-Faltungsvariante (rBet v 1-FV) bei allergischem Asthma bronchiale. Allergo Journal 22[6], 411. 2013.
\nRef Type: Abstract<\/p>\n
(23) \u00a0 Janicki S, Rudert M, Tribanek M, H\u00e4fner D, Narkus A. Neue objektive Methode zur Bestimmung der Intrakutantestreaktion (ICT). Allergo Journal 22[6], 412. 2013.
\nRef Type: Abstract<\/p>\n
(24) \u00a0 Kettner J, H\u00e4fner D, Meyer H, Weber B, Narkus A. Immunogenit\u00e4t der subkutanen spezifischen Immuntherapie (SCIT) mit hochdosierten hypoallergenen Pollenpr\u00e4paraten. Allergo Journal 22[6], 402. 2013.
\nRef Type: Abstract<\/p>\n
(25) \u00a0 Meyer W, Narkus A, Salapatek A M, H\u00e4fner D. Double-blind, placebo-controlled, dose-ranging study of new recombinant hypoallergenic Bet v 1 in an environmental exposure chamber. Allergy 2013; 68(6): 724-731.<\/p>\n
(26) \u00a0 Narkus A, Lehnigk U, Haefner D, Klinger R, Pfaar O, Worm M. The placebo effect in allergen-specific immunotherapy trials. Clin Transl Allergy 2013; 3(1): 42.<\/p>\n
(27) \u00a0 Rudert M, Tribanek M, Karjalainen M, Haefner D, Narkus A. New objective method to measure skin test results within clinical trials. Allergy 68[S97], 71-72. 2013.
\nRef Type: Abstract<\/p>\n
(28) \u00a0 H\u00e4fner D, Reich K, Zschocke I, Lotzin A, Meyer H, Kettner J, Narkus A. Prospective validation of the „rhino conjunctivitis allergy-control-SCORE(c)“ (RC-ACS(c)). Clin Transl Allergy 2012; 2(17): 1-8.<\/p>\n
(29) \u00a0 Herranz F, Schmidt-Weber C B, Shamji M H, Narkus A, Ruiz-Cabello J, Vilar R. Superparamagnetic iron oxide nanoparticles conjugated to a grass pollen allergen and an optical probe. Contrast Media Mol Imaging 2012; 7(4): 435-439.<\/p>\n
(30) \u00a0 Meyer W, Narkus A, Salapatek A, Patel D, Mussler S, Haefner D. Efficacy and safety of four dose regimes of a hypoallergenic recombinant birch pollen major allergen (rBet v 1-FV) in birch pollen allergic patients studied in an environmental exposure chamber. Allergy 67[S96], 89. 2012.
\nRef Type: Abstract<\/p>\n
(31) \u00a0 Meyer W, Narkus A, Salapatek A, Patel D, Mu\u00dfler S, H\u00e4fner D. Wirksamkeit und Vertr\u00e4glichkeit von 4 Dosierungen einer hypoallergenen, rekombinanten Faltungsvariante des Birkenpollenhauptallergens Bet v 1 bei Birkenpollenallergikern in einer Pollenkammer. Allergo Journal 21[S1], S46-S47. 2012.
\nRef Type: Abstract<\/p>\n
(32) \u00a0 Rak S, Valovirta E, Tribanek M, Haefner D, Narkus A, Meyer W. High-dose hypoallergenic birch pollen preparation is effective in Finland and Sweden. Allergy 67[S96], 526. 2012. Geneva, EAACI-Congress.
\nRef Type: Abstract<\/p>\n
(33) \u00a0 Rudert M, Kettner J, Haefner D, Narkus A, Thum-Oltmer S. Effects of the third year of specific immunotherapy with a high-dose hypoallergenic house dust mite preparation in children with allergic asthma. Allergy 67[S96], 525. 2012. Geneva, EAACI-Congress.
\nRef Type: Abstract<\/p>\n
(34) \u00a0 Rudert M, Kettner J, Haefner D, Narkus A. Early effect of high-dose hypoallergenic house dust mite preparation in the treatment of allergic asthma. Allergy 67[S96], 132. 2012. Geneva, EAACI-Congress.
\nRef Type: Abstract<\/p>\n
(35) \u00a0 Rudert M, Lehnigk U, Kettner J, H\u00e4fner D, Narkus A. Rascher Wirkeintritt der Hyposensibilisierung mit Acaroid bei Patienten mit allergischem Asthma gegen Hausstaubmilbe. Allergo Journal 21[S1], S52. 2012.
\nRef Type: Abstract<\/p>\n
(36) \u00a0 Rudert M, Karjalainen M, H\u00e4fner D, Thum-Oltmer S, Narkus A. Anhaltender Effekt im dritten Behandlungsjahr der spezifischen Immuntherapie mit Acaroid D. pteronyssinus bei Kindern und Jugendlichen mit allergischem Asthma bronchiale. Allergo Journal 21[S1], S53. 2012.
\nRef Type: Abstract<\/p>\n
(37) \u00a0 Schendzielorz P, Sprung V, Pfaar O, Mussler S, Meyer H, Narkus A. Spezifische subkutane Immuntherapie (SCIT) mit rekombinanten Graspollenallergenen: Erste randomisierte, doppelblinde, Plazebo-kontrollierte Dosisfindungsstudie. 2012. 83.Jahresversammlung der Deutschen Gesellschaft f\u00fcr Hals-Nasen-Ohren-Heilkunde, Kopf- und Hals-Chirurgie e.V.Deutsche Gesellschaft f\u00fcr Hals-Nasen-Ohren-Heilkunde, Kopf- und Hals-Chirurgie e.V.16.05.- 20.05.2012 Mainz.
\nRef Type: Report<\/p>\n
(38) \u00a0 Tribanek M, Narkus A, H\u00e4fner D, Meyer H. Die Subkutane Spezifische Immuntherapie mit einem hochdosierten Graspollenpr\u00e4parat reduziert die Anzahl der „Worst Days“. Allergo Journal 21[S1], S51. 2012.
\nRef Type: Abstract<\/p>\n
(39) \u00a0 Tribanek M, Narkus A, H\u00e4fner D, Meyer H. Eine Definition f\u00fcr „Curing Allergy“ – Ergebnisse einer Studie zur subkutanen Spezifischen Immuntherapie mit einem hochdosierten hypoallergenen Graspollenpr\u00e4parat. Allergo Journal 21[S1], S51. 2012.
\nRef Type: Abstract<\/p>\n
(40) \u00a0 Tribanek M, Narkus A, Haefner D, Meyer H. How to define ‚curing allergy‘? Results from a subcutaneous specific immunotherapy study using a high-dose hypoallergenic grass pollen preparation. Allergy 67[S96], 526. 2012. Geneva, EAACI-Congress.
\nRef Type: Abstract<\/p>\n
(41) \u00a0 Tribanek M, Narkus A, Haefner D, Meyer H. Subcutaneous specific immunotherapy with a high-dose hypoallergenic grass pollen preparation significantly reduces the number of worst days. Allergy 67[S96], 525-526. 2012. Geneva, EAACI-Congress.
\nRef Type: Abstract<\/p>\n
(42) \u00a0 Hansen S, Mu\u00dfler S, Meyer H, Narkus A, H\u00e4fner D. Sicherheit und Wirksamkeit der sublingualen Immuntherapie mit einem hochdosierten 6-Gr\u00e4serpollenpr\u00e4parat in einer randomisierten, doppelblinden, plazebokontrollierten Studie bei Kindern. Allergo Journal 20[S1], S11. 2011.
\nRef Type: Abstract<\/p>\n
(43) \u00a0 Hansen S, Cromwell O, Narkus A, H\u00e4fner D. First long-term efficacy data of subcutaneous specific immunotherapy with a recombinant birch pollen product. Allergy 66[S94], 62. 2011.
\nRef Type: Abstract<\/p>\n
(44) \u00a0 Hansen S, Mu\u00dfler S, Meyer H, H\u00e4fner D, Narkus A. Langzeituntersuchung der subkutanen Immuntherapie mit einer hypoallergenen rekombinanten Faltungsvariante des Birkenpollen-Hauptallergens Bet v 1 (rBet v 1-FV) 2 und 3 Jahre nach Beendigung der Therapie. Allergo Journal 20[S1], S13. 2011.
\nRef Type: Abstract<\/p>\n
(45) \u00a0 H\u00e4fner D, Reich K, Matricardi P M, Meyer H, Kettner J, Narkus A. Prospective validation of ‚Allergy-Control-SCORE(TM) ‚: a novel symptom-medication score for clinical trials. Allergy 2011; 66(5): 629-636.<\/p>\n
(46) \u00a0 Kettner J, Mussler S, H\u00e4fner D, Narkus A. Considerable 6 years post treatment long-term effect of pre-seasonal subcutaneous specific immunotherapy (SCIT) with a high-dose hypoallergenic grass pollen preparation. Allergy 66[S94], 296. 2011.
\nRef Type: Abstract<\/p>\n
(47) \u00a0 Kettner J, Lehnigk U, H\u00e4fner D, Narkus A. Lungenfunktion und bronchiale Hyperreaktivit\u00e4t bei Patienten mit allergischer Rhinokonjunktivitis. Allergo Journal 20[S1], S56. 2011.
\nRef Type: Abstract<\/p>\n
(48) \u00a0 Kettner J, Lehnigk U, H\u00e4fner D, Narkus A. A high-dose hypoallergenic house dust mite preparation improves lung function parameters in rhinoconjunctivitis patients with bronchial hyperreactivity. Allergy 66[S94], 295-296. 2011.
\nRef Type: Abstract<\/p>\n
(49) \u00a0 Kettner J, Mu\u00dfler S, H\u00e4fner D, Narkus A. Langzeit-Follow-up Untersuchung 6 Jahre nach subkutaner Immuntherapie (SCIT) mit Allergovit\u00ae <\/sup>Gr\u00e4ser. Allergo Journal 20[S1], S12. 2011.
\nRef Type: Abstract<\/p>\n(50) \u00a0 Kettner J, Mu\u00dfler S, Thum-Oltmer S, H\u00e4fner D, Narkus A. Subkutan applizierte hochdosierte, hypoallergene Gramineenpollen-Pr\u00e4parate: fr\u00fchzeitiger Wirkeintritt und Langzeit-Follow-Up-Daten f\u00fcr bis zu 12 Jahren nach Therapieende. Allergo Journal 20[S1], S12. 2011.
\nRef Type: Abstract<\/p>\n
(51) \u00a0 Lehnigk U, Kettner J, Haefner D, Cromwell O, Narkus A. Noticable placebo response in clinical studies investigating efficacy of different preparations for subcutaneous specific immunotherapy. Allergy 66[S94], 628. 2011.
\nRef Type: Abstract<\/p>\n
(52) \u00a0 Lehnigk U, Kettner J, H\u00e4fner D, Narkus A. Placeboeffekt in klinischen Studien zur Wirksamkeit subkutaner spezifischer Immuntherapie (SCIT). Allergo Journal 20[S1], S11-S12. 2011.
\nRef Type: Abstract<\/p>\n
(53) \u00a0 Matricardi PM, Kuna P, Wahn U, Narkus A. Subcutaneous Immunotherapy and Pharmacotherapy in Seasonal Allergic Rhinitis: A Comparison based on Meta-Analyses. Journal of Allergy & Clinical Immunology 127[2 S1], AB218. 2011.
\nRef Type: Abstract<\/p>\n
(54) \u00a0 Matricardi P M, Kuna P, Panetta V, Wahn U, Narkus A. Subcutaneous immunotherapy and pharmacotherapy in seasonal allergic rhinitis: A comparison based on meta-analyses. J Allergy Clin Immunol 2011; 128(4): 791-799.<\/p>\n
(55) \u00a0 Mussler S, Martin E, Thum-Oltmer S, H\u00e4fner D, Narkus A, Kettner J. High-dose hypoallergenic grass pollen preparation for subcutaneous specific immunotherapy: fast onset of efficacy and long-term effects for up to 12 years after termination. Allergy 66[S94], 134. 2011.
\nRef Type: Abstract<\/p>\n
(56) \u00a0 Mussler S, Thum-Oltmer S, Meyer H, Narkus A. Influence of high-dose grass pollen sublingual immunotherapy on allergic eye and nose symptoms. Allergy 65[S92], 73-74. 2010.
\nRef Type: Abstract<\/p>\n
(57) \u00a0 Mu\u00dfler S, Martin E, Thum-Oltmer S, Narkus A. Hochdosis-SLIT: nach 3-4 Monaten wirksamer als Antihistaminika bei saisonaler\/intermittierender allergischer Rhinokonjunktivitis. Allergo Journal 19[S1], S49-S50. 2010.
\nRef Type: Abstract<\/p>\n
(58) \u00a0 Mu\u00dfler S, Martin E, Thum-Oltmer S, Meyer H, Narkus A. Hochdosierte SLIT mit AllerSlit forte Gr\u00e4serpollen: bereits nach 3 Monaten hochwirksam auf allergische Augen- und Nasensymptome. Allergo Journal 19[S1], S63-S64. 2010.
\nRef Type: Abstract<\/p>\n
(59) \u00a0 Reich K, Haefner D, Meyer H, Kettner J, Narkus A. Prospective validation of a novel symptom-medication score for clinical trials. Allergy 65[S92], 5-6. 2010.
\nRef Type: Abstract<\/p>\n
(60) \u00a0 Rudert M, Meyer H, Gessner K, Haefner D, Narkus A. The optimal concentration range to diagnose a sensitisation to mugwort pollen through skin prick testing. Allergy 65[S92], 358. 2010.
\nRef Type: Abstract<\/p>\n
(61) \u00a0 Rudert M, Meyer H, Gessner K, Haefner D, Narkus A. The optimal concentration range to diagnose a sensitisation to birch pollen through skin prick testing. Allergy 65[S92], 355. 2010.
\nRef Type: Abstract<\/p>\n
(62) \u00a0 Rudert M, Meyer H, Gessner K, Haefner D, Narkus A. The optimal concentration range to diagnose a sensitisation to grass pollen through skin prick testing. Allergy 65[S92], 357. 2010.
\nRef Type: Abstract<\/p>\n
(63) \u00a0 Rudert M, Meyer H, Gessner K, Haefner D, Narkus A. The optimal concentration range to diagnose a sensitisation to house dust mites through skin prick testing. Allergy 65[S92], 357-358. 2010.
\nRef Type: Abstract<\/p>\n
(64) \u00a0 Kettner J, Mu\u00dfler S, Narkus A. Anhaltende Wirksamkeit 3 Jahre nach subkutaner spezifischer Immuntherapie (SCIT) mit Allergovit bei Patienten mit Gr\u00e4serpollenallergie im Vergleich zu nicht hyposensibilisierten Patienten. Allergo Journal 18[S1], S50. 2009.
\nRef Type: Abstract<\/p>\n
(65) \u00a0 Lang-Loidolt D, Tomazic P, K\u00f6le W, Narkus A. Significant increase of polysensitisation in allergic rhinoconjunctivitis among adolescent and adult patients living in urban areas since 1980. Allergy 64[S90], 329. 2009.
\nRef Type: Abstract<\/p>\n
(66) \u00a0 Martin E, Thum-Oltmer S, Mussler S, Meyer H, Narkus A. An abbreviated dose escalation scheme of a high-dose sublingual immunotherapy (SLIT) single dose preparation is safe and convenient in adults and children. Allergy 64[S90], 464-465. 2009.
\nRef Type: Abstract<\/p>\n
(67) \u00a0 Martin E, Thum-Oltmer S, Mu\u00dfler S, Narkus A. Querschnittsstudie Typ-1-Allergiker in Deutschland – Symptomatik und Behandlungsstatus. Allergo Journal 18[S1], S20. 2009.
\nRef Type: Abstract<\/p>\n
(68) \u00a0 Martin E, Thum-Oltmer S, Mussler S, Jaeschke B, Narkus A. Subcutaneous high dose hypoallergenic preparations in daily practice in more than 2900 allergic subjects \u2013 effective, safe and accepted by patients. Allergy 64[S90], 345-346. 2009.
\nRef Type: Abstract<\/p>\n
(69) \u00a0 Martin E, Thum-Oltmer S, Mussler S, Jaeschke B, Narkus A. Effective, well tolerated and accepted in daily practice: subcutaneous immunotherapy (SCIT) with aluminium hydroxide-adsorbed pollen extracts. Allergy 64[S90], 346. 2009.
\nRef Type: Abstract<\/p>\n
(70) \u00a0 Martin E, Thum-Oltmer S, Mu\u00dfler S, Jaeschke B, Narkus A. Wirksam, gut vertr\u00e4glich und akzeptiert in der \u00e4rztlichen Praxis: subkutane Immuntherapie (SCIT) mit Aluminiumhydroxid-adsorbierten Novo-Helisen-Depot-Pollenpr\u00e4paraten. Allergo Journal 18[S1], S52. 2009.
\nRef Type: Abstract<\/p>\n
(71) \u00a0 Martin E, Thum-Oltmer S, Mu\u00dfler S, Jaeschke B, Narkus A. Subkutane Immuntherapie (SCIT) mit dem hochdosierten hypoallergenen Pollenallergoid Allergovit – wirksam, sicher und akzeptiert in der t\u00e4glichen Praxis. Allergo Journal 18[S1], S28. 2009.
\nRef Type: Abstract<\/p>\n
(72) \u00a0 Martin E, Thum-Oltmer S, Mu\u00dfler S, Meyer H, Narkus A. Eine verk\u00fcrzte Aufdosierung im Verlauf der sublingualen Immuntherapie (SLIT) mit dem hochdosierten AllerSlit forte ist sicher und praktikabel bei Erwachsenen und Kindern. Allergo Journal 18[S1], S28. 2009.
\nRef Type: Abstract<\/p>\n
(73) \u00a0 Mussler S, Thum-Oltmer S, Martin E, Goerg M, Narkus A. Efficacy of sublingual immunotherapy with a high-dose 6-grass pollen preparation progressively increases in the third treatment year . Allergy 64[S90], 465. 2009.
\nRef Type: Abstract<\/p>\n
(74) \u00a0 Narkus A, Mussler S, Kettner J. Long-term follow-up of SCIT with a highdose hypo-allergenic six-grass pollen preparation: a comparison with nonhyposensitised patients. Allergy 64[S90], 346. 2009.
\nRef Type: Abstract<\/p>\n
(75) \u00a0 Rudert M, Kettner J, Narkus A. A high-dose hypo-allergenic mite preparation is effective in children with allergic asthma caused by house dust mite. Allergy 64[S90], 346-347. 2009.
\nRef Type: Abstract<\/p>\n
(76) \u00a0 Rudert M, Kettner J, Fiebig H, Narkus A. Hypoallergenic SCIT reduces inhaled corticosteroid use (ICS) in children with allergic asthma caused by house dust mites. 2009. ERS Congress, Vienna, September 12 – 16.
\nRef Type: Conference Proceeding<\/p>\n
(77) \u00a0 Sprung V, Pfaar O, Klimek L, Mussler S, Meyer H, Narkus A. Sicherheit und Wirksamkeit von rekombinanten Gr\u00e4serpollenallergenen – eine Dosis-Wirkungs-Studie. Allergo Journal 18[S1], S31. 2009.
\nRef Type: Abstract<\/p>\n
(78) \u00a0 Sprung V, Mussler S, Narkus A, H\u00e4fner D. Hat die spezifische Immuntherapie Einfluss auf Routinelaboruntersuchungen? Allergo Journal 18[S1], S50-S51. 2009.
\nRef Type: Abstract<\/p>\n
(79) \u00a0 Sprung V, Pfaar O, Klimek L, Mussler S, Meyer H, Narkus A. Safety and efficacy of recombinant grass pollen allergens: a dose \u2013 response study. Allergy 64[S90], 147. 2009.
\nRef Type: Abstract<\/p>\n
(80) \u00a0 Sprung V, Mussler S, Narkus A, H\u00e4fner D. Does allergen specific immunotherapy influence clinical chemistry and haematology laboratory parameters in adults? Allergy 64[S90], 356. 2009.
\nRef Type: Abstract<\/p>\n
(81) \u00a0 Fiebig H, Weber B, Narkus A, Cromwell O. Bet v 1-specific IgE-, IgG1- and IgG4-Antibody Responses after Immunotherapy with Hypoallergenic rBet v 1 or Birch Pollen Extract. Journal of Allergy & Clinical Immunology 121[2, S1], S141. 2008.
\nRef Type: Abstract<\/p>\n
(82) \u00a0 Kettner J, Mu\u00dfler S, Cromwell O, Narkus A. Langzeiteffekt der pr\u00e4saisonalen subkutanen Immuntherapie mit Allergovit bei erwachsenen Gr\u00e4serpollenallergikern. Allergo Journal 17[S2], S83. 2008.
\nRef Type: Abstract<\/p>\n
(83) \u00a0 Kettner J, Mussler S, Menzel A, Cromwell O, Narkus A. Preseasonal immunotherapy with a hypoallergenic six-grass pollen allergoid: a three year follow-up in adults. Allergy 63[S88], 494. 2008.
\nRef Type: Abstract<\/p>\n
(84) \u00a0 Kettner J, Sprung V, Meyer H, Cromwell O, Narkus A. Analyse der Wirksamkeit eines hypoallergenen Hochdosis-Gr\u00e4serpollen-extraktes (Allergovit) bezogen auf die Symptome der allergischen Rhinokonjunktivitis. Allergo Journal 17[S2], S84. 2008.
\nRef Type: Abstract<\/p>\n
(85) \u00a0 Kettner J, G\u00f6rg M, Cromwell O, Narkus A. Klinischer Erfolg im dritten Behandlungsjahr mit einer hochdosierten sublingualen Immuntherapie (HD-SLIT) bei Gr\u00e4serpollenallergie. Allergo Journal 17[S2], S88-S89. 2008.
\nRef Type: Abstract<\/p>\n
(86) \u00a0 Lang-Loidolt D, Jaeschke B, Narkus A. Upper respiratory symptoms in inhalative allergies are associated with sensitisations to outdoor allergens and monosensitizations. Allergy 63[S88], 224-225. 2008.
\nRef Type: Abstract<\/p>\n
(87) \u00a0 Lang-Loidolt D, Bruckmann L, Jaeschke B, Narkus A. Monosensitizations decreased significantly from 1980. Allergy 63[S88], 222-223. 2008.
\nRef Type: Abstract<\/p>\n
(88) \u00a0 Lang-Loidolt D, Jaeschke B, Narkus A. Sensitization-patterns changed from outdoor-allergens to outdoor and indoor-allergens within 20 years. Allergy 63[S88], 223. 2008.
\nRef Type: Abstract<\/p>\n
(89) \u00a0 Narkus A, Kniest F, Menzel A, Meyer H, Sprung V. Clinical trials with recombinant allergens – three perspectives: industry. Arb Paul Ehrlich Inst Bundesamt Sera Impfstoffe Frankf A M 2008; 96: 270-278.<\/p>\n
(90) \u00a0 Rudert M, Kettner J, Fiebig H, Narkus A. Wirksamkeit der spezifischen Immuntherapie mit Acaroid bei Kindern mit allergischem Asthma bronchiale gegen Hausstaubmilben. Allergo Journal 17[S2], S87. 2008.
\nRef Type: Abstract<\/p>\n
(91) \u00a0 Sprung V, Meyer H, Cromwell O, Narkus A. Immunotherapy with a fel d 1-standardized depot allergen from feline skin scales is clinically efficacious in respiratory cat allergy. Allergy 63[S88], 240. 2008.
\nRef Type: Abstract<\/p>\n
(92) \u00a0 Sprung V, Mu\u00dfler S, Meyer H, Weber B, Narkus A. Die spezifische immuntherapie mit einem Fel-d-1-standardisierten Depotpr\u00e4parat aus Katzen-Epithelien ist klinisch wirksame bei respiratorischer Katzenallergie. Allergo Journal 17[S2], S82. 2008.
\nRef Type: Abstract<\/p>\n
(93) \u00a0 Jost K, Meyer H, Suck R, Cromwell O, Narkus A. Specific immunotherapy with a hypoallergenic recombinant birch pollen allergen rBet v 1-FV is clinically efficacious: results of a phase III study. Allergo Journal 16[S1], S90. 2007.
\nRef Type: Abstract<\/p>\n
(94) \u00a0 Jost K, Weber B, Meyer H, Cromwell O, Narkus A. Specific immunotherapy with recombinant birch pollen allergen rBet v 1-FV: results of 2 years of treatment (phase II trial). Allergo Journal 16[S1], S91. 2007.
\nRef Type: Abstract<\/p>\n
(95) \u00a0 Kettner J, Meyer H, Narkus A, Cromwell O, Jost K. Specific Immunotherapy with Recombinant Birch Pollen Allergen rBet v 1-FV is Clinically efficacious \u2013 Results of a Phase III Study. Allergy 62[S83], 33. 2007.
\nRef Type: Abstract<\/p>\n
(96) \u00a0 Kettner J, Meyer H, Cromwell O, Narkus A, Jost K. Specific Immunotherapy with Recombinant Birch Pollen Allergen rBet v1-FV Results of 2 Years of Treatment (Phase II Trial). Allergy 62[S83], 262. 2007.
\nRef Type: Abstract<\/p>\n
(97) \u00a0 Kettner J, Narkus A, Meyer H, Cromwell O. Efficacious Management of House Dust Mite Allergy by 3 Years of Specific Immunotherapy with Allergen Extract. Allergy 62[S83], S264-S265. 2007.
\nRef Type: Abstract<\/p>\n
(98) \u00a0 Narkus A, Thum-Oltmer S, Mussler S, Meyer H, Cromwell O, Goerg M. Comparison of different preparations for sublingual immunotherapy using standardized mean differences. Allergo Journal 16[S1], S90-S91. 2007.
\nRef Type: Abstract<\/p>\n
(99) \u00a0 Thum-Oltmer S, Mussler S, Goerg M, Meyer H, Cromwell O, Narkus A. Comparison of Different Preparations for Sublingual Immunotherapy Using Standardized Mean Differences. Allergy 62[S83], 264. 2007.
\nRef Type: Abstract<\/p>\n
(100) \u00a0 Thum-Oltmer S, Mussler S, Meyer H, Narkus A. „Well days“ after subcutaneous immunotherapy with a high-dose hypoallergenic six-grass pollen preparation. Allergo Journal 16[S1], S89-S90. 2007.
\nRef Type: Abstract<\/p>\n
(101) \u00a0 Thum-Oltmer S, Mussler S, Meyer H, Narkus A. „Well days“ after immunotherapy with a high-dose sublingual grass pollen preparation. Allergo Journal 16[S1], S90. 2007.
\nRef Type: Abstract<\/p>\n
(102) \u00a0 Cromwell O, Fiebig H, Suck R, Kahlert H, Nandy A, Kettner J, Narkus A. Strategies for recombinant allergen vaccines and fruitful results from first clinical studies. Immunol Allergy Clin N Amer 2006; 26(2): 261-281.<\/p>\n
(103) \u00a0 Cromwell O, Narkus A. Clinical evaluation of recombinant allergens. Arb Paul Ehrlich Inst Bundesamt Sera Impfstoffe Frankf A M 2006; 95: 195-200.<\/p>\n
(104) \u00a0 Grewe M, Kettner J, Doemer C, Meyer H, Cromwell O, Narkus A. Efficacy and safety of specific immunotherapy with house dust mites allergen extract. Abstract Book EAACI 2006 , 227. 2006.
\nRef Type: Abstract<\/p>\n
(105) \u00a0 Merk H, Sprung V, Rudert M, St\u00fcwe H, J\u00e4ger L, Narkus A. Efficacy of a new purified wasp and bee venom preparation measured by sting challenge provocation test. Abstract Book EAACI 2006 , 229. 2006.
\nRef Type: Abstract<\/p>\n
(106) \u00a0 Narkus A. Sublinguale Immuntherapie – Voraussetzungen f\u00fcr eine optimale Wirksamkeit. Allergo Journal 15[S1], S50-S51. 2006.
\nRef Type: Abstract<\/p>\n
(107) \u00a0 Pfaar O, Bachert C, Doemer C, Meyer H, Narkus A, Klimek L. Spezifische Immuntherapie mit einer rekombinanten Birkenpollenallergen-Faltungsvariante rBet v 1-FV ist klinisch wirksam. Allergo Journal 15[1], 42. 2006.
\nRef Type: Abstract<\/p>\n
(108) \u00a0 Corrigan C J, Kettner J, Doemer C, Cromwell O, Narkus A. Efficacy and safety of preseasonal-specific immunotherapy with an aluminium-adsorbed six-grass pollen allergoid. Allergy 2005; 60(6): 801-807.<\/p>\n
(109) \u00a0 Dokic D, Schnitker J, Narkus A, Cromwell O, Frank E. Spezifische Immuntherapie mit einem neu entwickelten Hausstaubmilbenallergoid (Acaroid\u00ae). Eine doppelblinde, plazebokontrollierte Studie \u00fcber 2 Jahre mit einem Fortsetzungsjahr. Allergo J 2005; 14(5): 337-343.<\/p>\n
(110) \u00a0 Dokic D, Schnitker J, Narkus A, Cromwell O, Frank E. Clinical Effects of Specific Immunotherapy: A Two-year Double-blind, Placebo-controlled Study With a One Year Follow-Up. Prilozi 2005; 26(2): 113-129.<\/p>\n
(111) \u00a0 Frew A, Schnitker J, Kettner J, Doemer C, Cromwell O, Narkus A. Specific immunotherapy with house dust mites allergoid is safe and clinically efficacious. Allergy and Clinical Immunology International [Suppl.1], 527. 2005.
\nRef Type: Abstract<\/p>\n
(112) \u00a0 Henzgen M, Kettner J, Doemer C, Cromwell O, Narkus A. Efficacious management of allergic rhinitis by three years of pre-seasonal specific immunotherapy with a grass pollen allergoid. Allergy and Clinical Immunology International [Suppl.1], 518-519. 2005.
\nRef Type: Abstract<\/p>\n
(113) \u00a0 Klimek L, Bachert C, Doemer C, Meyer H, Narkus A. Specific immunotherapy with recombinant birch pollen allergen rBet v1-FV is clinically efficacious. Allergy and Clinical Immunology International [Suppl.1], 15. 2005.
\nRef Type: Abstract<\/p>\n
(114) \u00a0 Kowalski M, Rudert M, Stuewe HT, Cromwell O, Narkus A. Specific immunotherapy with a new purified bee venom. Allergy and Clinical Immunology International [Suppl.1], 519. 2005.
\nRef Type: Abstract<\/p>\n
(115) \u00a0 Merk HF, Erdmann S, Sprung V, Stuewe HT, Jaeger L, Narkus A. Immunotherapy of wasp venom allergy: Comparison of a new purified and standardised wasp venom preparation with a conventional wasp venom. Allergy and Clinical Immunology International [Suppl.1], 527. 2005.
\nRef Type: Abstract<\/p>\n
(116) \u00a0 Corrigan CJ, Kettner J, Doemer C, Narkus A. A grass pollen allergoid is clinically efficacious in the management of allergic rhinitis. Abstract Book EAACI 2004, 138. 2004. EAACI-Kongress Amsterdam.
\nRef Type: Abstract<\/p>\n
(117) \u00a0 Hansen I, H\u00f6rmann K, Klimek L, Kettner J, Narkus A. Cluster-Immuntherapie bei allergischer Rhinokonjunktivitis und Asthma bronchiale: Sicherheit der Initialtherapie mit Novo-Helisen Depot. Allergologie 2004; 27(12): 477-483.<\/p>\n
(118) \u00a0 Jutel M, Jaeger L, Meyer H, Cromwell O, Narkus A. Specific immunotherapy with recombinant grass pollen allergens is clinically efficacious. 2004. EAACI-Congress Amsterdam.
\nRef Type: Conference Proceeding<\/p>\n<\/div>
<\/div><\/div><\/div><\/div><\/div><\/p>\n","protected":false},"excerpt":{"rendered":"","protected":false},"author":1,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"open","ping_status":"open","template":"100-width.php","meta":{"footnotes":""},"class_list":["post-14281","page","type-page","status-publish","hentry"],"aioseo_notices":[],"_links":{"self":[{"href":"https:\/\/www.mc-narkus.de\/en\/wp-json\/wp\/v2\/pages\/14281","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.mc-narkus.de\/en\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/www.mc-narkus.de\/en\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/www.mc-narkus.de\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.mc-narkus.de\/en\/wp-json\/wp\/v2\/comments?post=14281"}],"version-history":[{"count":26,"href":"https:\/\/www.mc-narkus.de\/en\/wp-json\/wp\/v2\/pages\/14281\/revisions"}],"predecessor-version":[{"id":14397,"href":"https:\/\/www.mc-narkus.de\/en\/wp-json\/wp\/v2\/pages\/14281\/revisions\/14397"}],"wp:attachment":[{"href":"https:\/\/www.mc-narkus.de\/en\/wp-json\/wp\/v2\/media?parent=14281"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}